Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2006 Jul;80(14):7127-35.
doi: 10.1128/JVI.02619-05.

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1

C P Krachmarov  1 , W J Honnen, S C Kayman, M K Gorny, S Zolla-Pazner, Abraham Pinter
Affiliations
Comparative Study

Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1

C P Krachmarov et al. J Virol. 2006 Jul.

Abstract

The neutralizing activities of anti-V3 antibodies for HIV-1 isolates is affected both by sequence variation within V3 and by epitope masking by the V1/V2 domain. To analyze the relative contribution of V3 sequence variation, chimeric Env genes that contained consensus V3 sequences from seven HIV-1 subtypes in the neutralization-sensitive SF162 Env backbone were constructed. Resulting viral pseudotypes were tested for neutralization by 15 anti-V3 MAbs isolated from humans infected with viruses of either subtype B (anti-V3(B) MAbs) or subtype A (anti-V3(A) MAbs). Pseudovirions with the subtype B consensus V3 sequence were potently neutralized (IC(50) < 0.006 microg/ml) by all but one of these MAbs, while pseudovirions with V3 subtypes A, C, F, H, AG, and AE were generally neutralized more effectively by anti-V3(A) MAbs than by anti-V3(B) MAbs. A V1/V2-masked Env version of SF162 Env with the consensus B V3 sequence was also neutralized by these MAbs, although with considerably lower potency, while similarly masked chimeras with V3 sequences of subtype A, C, or AG were weakly neutralized by anti-V3(A) MAbs but not by anti-V3(B) MAbs. Mutations in the V1/V2 domain of YU-2 Env increased the sensitivity of this highly resistant Env to a pool of anti-V3(B) MAbs several thousand-fold. These results demonstrated (i) the exceptional sensitivity of representative V3 domains of multiple subtypes to neutralization in the absence of epitope masking, (ii) the broader neutralizing activity of anti-V3(A) MAbs for viruses containing diverse V3 sequences, and (iii) the generality and dominant effect of V1/V2 masking on restriction of V3-mediated neutralization.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
(A) Structures of chimeric envelopes used for examining the roles of the V1/V2 domains on neutralization sensitivity of V3 epitopes. Chimeric envelopes were constructed in the SF162 backbone (gray bars) by exchanging the V1/V2 and/or V3 domains with the corresponding domains of JR-FL Env (white bars). (B) Comparison of V3 loop sequences of JR-FL and SF162 Env proteins.
FIG. 2.
FIG. 2.
Structures of chimeric envelopes used for preparing HIV-1 pseudotypes. (A) Model of chimeric Envs used in these studies. The Envs utilized the SF162 backbone (gray bars) with modified V3 sequences (white bars). The V1/V2 domains of several of the V3 chimeric Envs were replaced by that of JR-FL, resulting in epitope-masked Envs which were relatively resistant to V3-mediated neutralization. (B) Sequences of substituted V3 domains. Residues that vary from the subtype B consensus sequence residues are indicated.
FIG. 3.
FIG. 3.
Neutralization curves obtained for pooled anti-V3B MAbs against SF162 Env with the consensus B V3 sequence (circles), SF162 Env with the YU-2 V2 sequence (triangles), parental YU-2 Env (squares), and YU-2 Env in which the indicated four positions in the V1/V2 domain were mutated (diamonds).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Binley, J. M., T. Wrin, B. Korber, M. B. Zwick, M. Wang, C. Chappey, G. Stiegler, R. Kunert, S. Zolla-Pazner, H. Katinger, C. J. Petropoulos, and D. R. Burton. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252. - PMC - PubMed
    1. Bou-Habib, D. C., G. Roderiquez, T. Oravecz, P. W. Berman, P. Lusso, and M. A. Norcross. 1994. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68:6006-6013. - PMC - PubMed
    1. Burton, D. R., R. C. Desrosiers, R. W. Doms, W. C. Koff, P. D. Kwong, J. P. Moore, G. J. Nabel, J. Sodroski, I. A. Wilson, and R. T. Wyatt. 2004. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5:233-236. - PubMed
    1. Burton, D. R., J. Pyati, R. Koduri, S. J. Sharp, G. B. Thornton, P. W. Parren, L. S. Sawyer, R. M. Hendry, N. Dunlop, P. L. Nara, et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027. - PubMed
    1. Candotti, D., M. Rosenheim, J. M. Huraux, and H. Agut. 1997. Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates. J. Virol. Methods 64:81-93. - PubMed

Publication types

MeSH terms

LinkOut - more resources